Metaclipse Therapeutics
- Biotech or pharma, therapeutic R&D
Metaclipse Therapeutics is a biotech company developing next-gen immunotherapies for cancer and vaccines for infectious diseases. Its proprietary biological adjuvant platform enhances immune responses by linking membrane-bound cytokines/immunostimulants to antigens.
Membrex™, its lead personalized cancer vaccine, combines patient-derived tumor antigens with adjuvants to combat checkpoint inhibitor resistance. Phase 1 trials in TNBC and head & neck cancer are currently in progress, backed by a $6M Cancer Research and Prevention Institute of Texas (CPRIT) grant.
VaxRex™, its VLP-based vaccine platform, targets viruses (e.g., flu, COVID-19, HIV) with potent immunity, especially for elderly/immunocompromised individuals.
Metaclipse plans to license its tech to pharma through strategic partnerships post-proof-of-concept. Supported by Texas Medical Center Innovation (TMCi)/CPRIT, it aims to transform immunotherapy with rapid and cost-effective solutions.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}